Brownlie, Helen, Speight, Nigel · Healthcare (Basel, Switzerland) · 2021 · DOI
This review examined past studies on intravenous immunoglobulin (IV IgG), a blood-based treatment, for ME/CFS. The authors found that while results were previously thought to be mixed, a closer look suggests IV IgG may actually help a meaningful group of patients—particularly those with severe ME/CFS who have specific immune system markers. Some patients experienced temporary worsening of symptoms like headaches during treatment, which may actually indicate the treatment was working rather than causing harm.
This analysis challenges the dismissal of IV IgG as ineffective for ME/CFS and suggests treatment may benefit a specifically identifiable subset of patients with severe disease. This could redirect clinical attention and research funding toward a potentially valuable intervention for the most severely affected patients who currently have limited treatment options.
This systematic review does not establish that IV IgG is effective for all ME/CFS patients or that symptom worsening during treatment definitively indicates clinical improvement. The review also cannot determine causality or identify which specific immune markers most reliably predict responders without additional prospective studies. Finally, it does not establish efficacy in post-COVID conditions, only noting that this area warrants future investigation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Brownlie, Helen & Speight, Nigel (2021). Back to the Future? Immunoglobulin Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.. Healthcare (Basel, Switzerland). https://doi.org/10.3390/healthcare9111546
BibTeX
@article{mecfsatlas-brownlie-2021-back-future,
author = {Brownlie, Helen and Speight, Nigel},
title = {Back to the Future? Immunoglobulin Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.},
journal = {Healthcare (Basel, Switzerland)},
year = {2021},
doi = {10.3390/healthcare9111546},
note = {PubMed: 34828592},
url = {https://www.mecfsatlas.com/evidence/brownlie-2021-back-future},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-28. https://www.mecfsatlas.com/evidence/brownlie-2021-back-future
Contribute
Private, reviewed by a human. Not a public comment thread.